(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes...
Stats | |
---|---|
Šios dienos apimtis | 13.77M |
Vidutinė apimtis | 7.44M |
Rinkos kapitalizacija | 5.26B |
EPS | £0 ( 2024-03-05 ) |
Last Dividend | £1.380 ( 2023-08-17 ) |
Next Dividend | £0 ( N/A ) |
P/E | 51.56 |
ATR14 | £0.438 (0.17%) |
Tūris Koreliacija
ConvaTec Group PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
GHT.L | 0.837 |
DWF.L | 0.827 |
NTOG.L | 0.817 |
3SAP.L | 0.811 |
MCM.L | 0.809 |
CNIC.L | 0.807 |
WINE.L | 0.806 |
SBEM.L | 0.805 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
ConvaTec Group PLC Koreliacija - Valiuta/Žaliavos
ConvaTec Group PLC Finansinės ataskaitos
Annual | 2023 |
Pajamos: | £2.14B |
Bruto pelnas: | £1.20B (56.04 %) |
EPS: | £0.0640 |
FY | 2023 |
Pajamos: | £2.14B |
Bruto pelnas: | £1.20B (56.04 %) |
EPS: | £0.0640 |
FY | 2022 |
Pajamos: | £2.07B |
Bruto pelnas: | £1.12B (53.92 %) |
EPS: | £0.0311 |
FY | 2021 |
Pajamos: | £2.04B |
Bruto pelnas: | £1.12B (55.10 %) |
EPS: | £0.0590 |
Financial Reports:
No articles found.
ConvaTec Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£1.410 (N/A) |
£0 (N/A) |
£0 (N/A) |
£3.66 (N/A) |
£1.380 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.061 | 2017-09-07 |
Last Dividend | £1.380 | 2023-08-17 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | £28.05 | -- |
Avg. Dividend % Per Year | 1.46% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 8.79 | |
Div.Growth Potential Score | 3.50 | |
Div. Directional Score | 6.14 | -- |
Year | Amount | Yield |
---|---|---|
2017 | £0 | 0.00% |
2018 | £4.40 | 2.05% |
2019 | £4.50 | 3.31% |
2020 | £4.40 | 2.23% |
2021 | £4.08 | 1.99% |
2022 | £4.57 | 2.36% |
2023 | £5.04 | 2.16% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WTB.L | Dividend Knight | 2023-05-25 | Annually | 33 | 0.87% | |
NTV.L | Dividend Knight | 2023-07-20 | Semi-Annually | 25 | 4.03% | |
EMG.L | Dividend King | 2023-08-10 | Semi-Annually | 31 | 3.60% | |
SPT.L | Dividend Knight | 2023-08-10 | Semi-Annually | 32 | 1.51% | |
JD.L | Dividend Knight | 2023-12-07 | Annually | 28 | 0.21% | |
BUT.L | Dividend King | 2023-08-03 | Quarterly | 49 | 1.28% | |
PNL.L | Dividend Knight | 2023-08-24 | Quarterly | 41 | 0.75% | |
FSFL.L | Dividend Knight | 2023-07-20 | Quarterly | 11 | 3.85% | |
AERI.L | Dividend Junior | 2023-08-17 | Quarterly | 6 | 2.80% | |
THRG.L | Dividend Knight | 2023-08-03 | Semi-Annually | 52 | 1.02% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0608 | 1.500 | 8.78 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0351 | 1.200 | 8.83 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0785 | 1.500 | -0.239 | -0.358 | [0.1 - 1] |
payoutRatioTTM | 0.850 | -1.000 | 1.504 | -1.504 | [0 - 1] |
currentRatioTTM | 1.622 | 0.800 | 6.89 | 5.51 | [1 - 3] |
quickRatioTTM | 0.686 | 0.800 | -0.669 | -0.535 | [0.8 - 2.5] |
cashRatioTTM | 0.182 | 1.500 | -0.100 | -0.150 | [0.2 - 2] |
debtRatioTTM | 0.353 | -1.500 | 4.11 | -6.17 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.177 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.115 | 2.00 | 9.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.775 | -1.500 | 6.90 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.562 | 1.000 | 3.97 | 3.97 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.131 | 1.000 | 9.39 | 9.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.280 | 1.000 | 9.56 | 9.56 | [0.2 - 2] |
assetTurnoverTTM | 0.577 | 0.800 | 9.49 | 7.59 | [0.5 - 2] |
Total Score | 8.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 51.24 | 1.000 | 4.93 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0785 | 2.50 | -0.153 | -0.358 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.115 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.520 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.177 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.850 | 1.500 | 1.504 | -1.504 | [0 - 1] |
pegRatioTTM | -63.57 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.171 | 1.000 | 8.21 | 0 | [0.1 - 0.5] |
Total Score | 3.50 |
ConvaTec Group PLC
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.